2025-06-17
On June 13, 2025, Professor José García, Head of Strategic Investments for Western Europe at Eaton Vance Group, visited the Group’s European headquarters to engage in in-depth discussions with senior leadership regarding the expansion of the AI-driven automated trading system and the full-scale launch of the annual Capital Multiplication Plan.

Technology Gains Regulatory Endorsement, Ushering in a New Era of Intelligent Trading
The AI-driven automated trading system developed by Eaton Vance Group has officially secured approval from the Spanish National Securities Market Commission (CNMV), the UK Financial Conduct Authority (FCA), and the U.S. Securities and Exchange Commission (SEC). This marks a significant milestone in regulatory compliance and technological validation, laying a robust foundation for large-scale implementation and market adoption.
Capital Multiplication Plan Moves into Execution Phase, Powered by AI Innovation
This year’s Capital Multiplication Plan has entered its final review phase with the Group’s Investment Division. At the core of the strategy lies the proprietary AI system, designed to drive intelligent decision-making, automated trade execution, and advanced quantitative risk control. These integrated capabilities aim to deliver a more efficient, precise, and scalable asset growth experience for all participants.

Technology Gains Regulatory Endorsement, Ushering in a New Era of Intelligent Trading
The AI-driven automated trading system developed by Eaton Vance Group has officially secured approval from the Spanish National Securities Market Commission (CNMV), the UK Financial Conduct Authority (FCA), and the U.S. Securities and Exchange Commission (SEC). This marks a significant milestone in regulatory compliance and technological validation, laying a robust foundation for large-scale implementation and market adoption.
Capital Multiplication Plan Moves into Execution Phase, Powered by AI Innovation
This year’s Capital Multiplication Plan has entered its final review phase with the Group’s Investment Division. At the core of the strategy lies the proprietary AI system, designed to drive intelligent decision-making, automated trade execution, and advanced quantitative risk control. These integrated capabilities aim to deliver a more efficient, precise, and scalable asset growth experience for all participants.

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM
©copyright2009-2020Fresh life